Cone-rod dystrophy 11 is a genetic eye condition that affects the cone and rod cells of the retina. People with cone-rod dystrophy 11 often notice early symptoms of light sensitivity, reduced central vision, and later trouble seeing in dim light. Vision changes usually begin in childhood or adolescence and tend to be progressive over time. Not everyone will have the same experience, and severity can vary by gene variant and family. There is no cure, and treatment focuses on low-vision aids, tinted lenses, and supportive care, while regular follow-up helps protect eye health and safety.
Overview
Cone-rod dystrophy 11Symptoms
Early symptoms of Cone-rod dystrophy 11 include blurry central vision, light sensitivity, and difficulty distinguishing colors. As it progresses, many develop night blindness and narrowing peripheral vision, which can make reading, driving, and recognizing faces harder.
Outlook and prognosis
Many living with cone-rod dystrophy 11 notice vision changes starting with daytime glare, color loss, and reading difficulty, followed by slower night and side-vision problems. Progression is typically gradual over years. Low-vision care, tinted lenses, and support services help maintain independence.
Causes and risk factors
Cone-rod dystrophy 11 is caused by pathogenic changes in a single gene, typically inherited. Risk is highest with family history or parents who are related. Lifestyle and environmental factors don’t cause it, though overall eye health may influence symptom burden.
Genetic influences
Genetics are central in Cone-rod dystrophy 11; it’s caused by inherited gene changes, most often affecting photoreceptor function. Variants can run in families with autosomal dominant or recessive patterns. Different mutations influence age at onset, severity, and progression.
Diagnosis
Doctors suspect cone-rod dystrophy 11 when vision tests show early cone loss with later rod involvement. Diagnosis is confirmed with retinal imaging, electroretinography, and genetic tests. Genetic diagnosis of cone-rod dystrophy 11 helps guide counseling and family screening.
Treatment and drugs
Treatment for cone-rod dystrophy 11 focuses on protecting vision, easing symptoms, and supporting daily life. This can include tinted lenses for light sensitivity, low‑vision aids, orientation training, and regular eye care. Genetic counseling and clinical‑trial discussions may also be helpful.
Symptoms
Vision changes often begin in bright settings, with trouble seeing fine detail or colors. Early features of Cone-rod dystrophy 11 often include glare sensitivity, fading color vision, and blur in the center of sight. Features vary from person to person and can change over time.
Fine print, faces, or street signs can look fuzzy, especially in bright light. In Cone-rod dystrophy 11, the center of sight is often the first area that feels less sharp.
Reds, greens, or blues may look faded or harder to tell apart. This can make matching clothes or reading color-coded labels tougher.
Bright or flickering light can feel harsh. Sunlight, glossy pages, or LED screens may create glare that washes out detail.
Dim rooms and nighttime streets can be hard to make out. In Cone-rod dystrophy 11, many notice they need more time to adjust when moving from light to dark.
How people usually first notice Cone-rod dystrophy 11?
Families often first notice cone-rod dystrophy 11 when a child struggles to see colors accurately or squints in bright light, with complaints that daylight feels harsh or that reds and greens look “off.” As school begins, many parents spot early vision problems like difficulty reading the board, needing to move closer to screens, or developing central blurry spots, which are common first signs of cone-rod dystrophy 11. Eye doctors typically confirm how cone-rod dystrophy is first noticed with tests showing reduced cone function in the center vision and, over time, milder night or peripheral vision changes as rod cells become involved.
Types of Cone-rod dystrophy 11
Cone-rod dystrophy 11 is a genetic eye condition with a few recognized clinical variants, which can affect color vision, light sensitivity, and clarity of sight in different ways. People may notice different sets of symptoms depending on their situation. Variants are typically defined by the specific gene change and whether one or both copies are affected. Knowing the types of Cone-rod dystrophy 11 can help explain why symptoms start earlier for some and progress differently for others.
Autosomal recessive
Both copies of the CRX-related gene are altered. Symptoms often begin in childhood or the teen years with early color vision loss, glare, and central blurring. Night vision and side vision may decline later as rods become involved.
Autosomal dominant
One altered copy of the CRX gene is enough to cause symptoms. Onset is often later, ranging from teens to adulthood, and severity can vary widely within families. Some keep usable vision for many years, while others progress faster.
De novo dominant
A new CRX change appears for the first time in the individual. Family history is absent, but features mirror the dominant pattern with variable timing and speed. Genetic testing confirms the variant when types of Cone-rod dystrophy 11 are unclear.
Macular-predominant
Vision changes center on the macula, affecting sharp central vision first. People may have trouble reading small print or recognizing faces before side or night vision is affected. Peripheral and night vision can remain better preserved for a time.
Generalized cone-rod
Both cone and rod cells are affected more broadly. Light sensitivity, color problems, and central blur appear early, followed by night blindness and reduced side vision. Even within the same type, intensity can range from mild to severe.
What genetics can tell you about symptoms
Some people with cone-rod dystrophy 11 develop early color vision problems and light sensitivity because changes in the ABCA4 gene disrupt cone cells first. As the same faulty gene also affects rod cells over time, night blindness and shrinking side vision often follow.
Causes and risk factors
Cone-rod dystrophy 11 is caused by a harmful change in a single gene that disrupts cone and rod cells in the retina. The change may be inherited from a parent or occur as a new mutation, so family history raises risk. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). When a family has a recessive form, closely related parents have a higher chance of having an affected child. Genetic testing clarifies personal risk better than early symptoms of Cone-rod dystrophy 11, and UV protection and not smoking support eye health.
Environmental and biological risk factors
We focus here on environmental and biological factors that may influence how often Cone-rod dystrophy 11 occurs. Some risks are carried inside the body, others come from the world around us. For many families, these influences are small, but understanding them can help with planning. Below are environmental and biological risk factors for Cone-rod dystrophy 11.
Older paternal age is linked to a higher number of new DNA changes in sperm. This can slightly raise the chance that a condition like Cone-rod dystrophy 11 appears for the first time in a family. The absolute risk remains low.
Older maternal age is associated with a higher chance of new changes arising at conception. Most pregnancies are unaffected, but this can modestly increase the likelihood of a condition caused by a change in one gene.
High-dose radiation to either parent before conception can damage reproductive cells. This may increase the chance of new DNA changes, though the overall risk for Cone-rod dystrophy 11 remains very low. Standard medical imaging uses far lower doses and is not a concern.
Some chemotherapy medicines and pelvic or whole-body radiation can affect eggs or sperm. These exposures may raise the chance of new DNA changes; any added risk for this specific condition is still small. Talk with your care team about timing of pregnancy after treatment.
Genetic risk factors
Inherited DNA changes are the core driver of Cone-rod dystrophy 11, affecting how cone and rod cells function over time. Some risk factors are inherited through our genes. A confirmed genetic change in a single retina gene explains most cases, and genetic testing can identify the exact change and who else may be at risk, sometimes even before early symptoms of Cone-rod dystrophy 11 appear. The way it runs in families can differ, so the chance of passing it on depends on the specific inheritance in your family.
Single-gene change: Cone-rod dystrophy 11 results from a disease-causing change in one gene that supports cone and rod cells. These DNA changes disrupt how the retina senses and processes light.
Inheritance pattern: The way Cone-rod dystrophy 11 runs in a family depends on the specific gene change. Once the exact change is identified, a genetics professional can give clear estimates for risks to children and siblings.
New (de novo): Sometimes the gene change occurs for the first time in a person, with no prior family history. Parents can test negative while the child carries the change and can pass it on.
Variable severity: People with the same gene change can have different ages when symptoms begin and different rates of vision change. This variability can show up even among close relatives.
Different DNA changes: Various kinds of DNA changes can interfere with the gene’s job. The specific change can influence when Cone-rod dystrophy 11 starts and how quickly it progresses.
Family history clues: Vision problems appearing across several generations suggest an inherited pattern. Lack of family history does not rule out a genetic cause, especially when a new change is present.
Subtype differences: Similar cone-rod dystrophy features can come from changes in other retina genes. Genetic testing clarifies whether it is Cone-rod dystrophy 11 or another related subtype, which also guides family risk.
Lifestyle risk factors
Cone-rod dystrophy 11 is genetic and not caused by habits, but how lifestyle affects Cone-rod dystrophy 11 can influence day-to-day vision, symptom burden, and risk of added eye problems. Choices around light exposure, smoking, nutrition, activity, sleep, alcohol, and metabolic health may change glare sensitivity, visual fatigue, and long-term retinal stress. Evidence specific to CRD11 is limited, but data from retinal biology and related macular diseases guide these practical considerations. Discuss any changes with your eye specialist to tailor them to your vision needs.
Frequent exposure to intense light can worsen photophobia, afterimages, and visual fatigue in CRD11. Consistent use of hats and high-quality tinted lenses may reduce light-triggered symptoms and improve functional vision.
Tobacco and nicotine increase retinal oxidative stress and reduce choroidal circulation, which can strain already vulnerable photoreceptors in CRD11. Quitting lowers oxidative load and may slow symptom worsening.
Low intake of colorful fruits and vegetables may deprive the macula of carotenoids and antioxidants that buffer oxidative stress. Adequate lutein, zeaxanthin, and vitamin-rich foods may support contrast sensitivity and glare recovery in CRD11.
Sparse omega-3 (DHA/EPA) intake can reduce the lipid nutrients critical for photoreceptor membranes. Regular fish or algae-based omega-3s may support retinal resilience and reduce visual discomfort in CRD11.
Risk prevention
For people living with cone-rod dystrophy 11, you can’t change the gene variant that causes it, but you can protect remaining vision and avoid extra eye strain. Prevention is about lowering risk, not eliminating it completely. Regular eye care can catch treatable issues like swelling or cataracts early, which may help preserve function. Knowing early symptoms of cone-rod dystrophy 11 can also prompt timely checks and support.
Schedule comprehensive dilated exams with retinal imaging to monitor for changes. Catching complications early allows treatment that may protect vision.
Wear UV-blocking sunglasses and a brimmed hat outdoors to reduce light sensitivity and potential retinal stress. Tinted lenses or filters can make bright environments more comfortable for people with cone-rod dystrophy 11.
Avoid smoking and secondhand smoke, which can harm the retina’s blood supply. Staying smoke-free supports overall eye health in cone-rod dystrophy 11.
Keep blood pressure, cholesterol, and blood sugar in a healthy range to support retinal circulation. Good general health helps protect remaining vision.
Transmission
Cone-rod dystrophy 11 is a genetic condition and cannot be caught from someone else. It is most often inherited in an autosomal dominant pattern, meaning a change in one copy of the gene is enough to cause it, and each child of an affected parent has a 50% chance of inheriting the condition.
Sometimes Cone-rod dystrophy 11 appears for the first time in a family because of a new genetic change; in that case, the chance it will happen again in future siblings is generally low, while the affected person can still pass it on to their children. If you have questions about the genetic transmission of Cone-rod dystrophy 11 or how Cone-rod dystrophy 11 is inherited, a genetics professional can review your family history and discuss testing.
When to test your genes
Cone-rod dystrophy 11 is genetic, so consider testing if you have early vision changes (reduced sharpness, poor color vision, light sensitivity), a family history of similar eye disease, or an identified mutation in a relative. Testing helps confirm the diagnosis, guide monitoring, and inform low-vision supports. It also clarifies recurrence risks for family planning.
Diagnosis
For many, the first step comes when everyday activities start feeling harder—words on a page blur, bright light feels harsh, or colors seem washed out. Doctors look for a consistent pattern of central vision loss, color changes, and specific retinal findings to guide the diagnosis of Cone-rod dystrophy 11. Getting a diagnosis is often a turning point toward answers and support. When clinical signs point to this condition, the genetic diagnosis of Cone-rod dystrophy 11 is confirmed with targeted testing.
Your provider asks about night glare, light sensitivity, color changes, and reading difficulty. The timing and pace of changes help distinguish cone-rod dystrophy from other eye conditions.
Doctors check visual acuity, pupils, eye movements, and lens and retina health. They look for macular changes that fit the cone-first, then rod pattern seen in cone-rod dystrophy.
Simple plates or more detailed color arrangement tests measure how well you see reds, greens, and blues. Reduced color discrimination supports a cone-driven problem early on.
A perimetry exam maps blind spots and overall field loss. Central deficits are common early, with wider field changes as the condition progresses.
Stages of Cone-rod dystrophy 11
Cone-rod dystrophy 11 does not have defined progression stages. It tends to progress at different speeds from person to person, and changes are followed using vision tests and retinal scans rather than set milestones; early symptoms of Cone-rod dystrophy 11 may include difficulty seeing fine details and sensitivity to light, with night or side-vision problems appearing later. Different tests may be suggested to help confirm the diagnosis and track how your vision changes over time. This typically includes a thorough eye exam, color and visual-field testing, detailed photos or scans of the retina, an electrical test of retinal function when needed, and genetic testing to look for the underlying change.
Outlook and prognosis
Looking ahead can feel daunting, but most people with cone-rod dystrophy 11 (CORD11) find that planning around vision changes helps daily life feel more predictable. Many people ask, “What does this mean for my future?”, and for CORD11 it usually means central vision declines first, with trouble reading small print, recognizing faces, or handling glare; later, peripheral and night vision can also fade. Everyone’s journey looks a little different. Some people notice a slow, decades-long change, while for others vision drops more quickly in the teens or early adulthood.
Doctors call this the prognosis—a medical word for likely outcomes. CORD11 is typically progressive, and many living with cone-rod dystrophy 11 eventually meet criteria for legal blindness, though complete darkness is uncommon. The early symptoms of cone-rod dystrophy 11 often include color vision loss and light sensitivity, and the pace of change after that can vary by gene variant and family pattern. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. There’s no cure yet, but low-vision tools, tinted lenses, orientation and mobility training, and workplace or school accommodations can protect independence and safety.
Mortality with cone-rod dystrophy 11 is not increased; it affects vision, not life span. With ongoing care, many people maintain work, school, and strong social lives, adapting as needs change. Genetic testing can sometimes provide more insight into prognosis. Talk with your doctor about what your personal outlook might look like, including how often to monitor changes and which aids or services could help right now.
Long-term effects
Cone-rod dystrophy 11 usually leads to gradual loss of sharp, color vision first, followed by problems seeing in dim light and shrinking side vision over time. Long-term effects vary widely, with some people noticing changes in childhood while others progress slowly into adulthood. Early symptoms of cone-rod dystrophy 11 can include glare sensitivity, trouble reading fine print, and faded colors. The overall outlook is progressive, but the pace and final level of vision can differ from one person to the next.
Reading, screens, and recognizing faces become harder as fine detail fades. Visual acuity often declines over years, and some eventually meet criteria for legal blindness. The timeline can differ widely.
Colors may look washed out, and telling similar shades apart becomes difficult. Red–green and blue–yellow mix-ups can appear early and tend to progress. This can make color-coded information harder to use.
Bright light can feel harsh or painful, and glare may obscure details. Moving from dim to bright settings can be disorienting. Indoor lighting and sunlight can both trigger discomfort.
Seeing in dim light becomes difficult, and adapting from bright to dark takes longer. Navigating unlit streets or movie theaters may feel unsafe or confusing. This often worsens as rods are affected over time.
How is it to live with Cone-rod dystrophy 11?
Living with cone-rod dystrophy 11 often means adapting to changing vision—colors may fade, bright light can feel harsh, and fine details become harder to see, especially for reading, recognizing faces, or navigating unfamiliar places. Many find that sunglasses with strong UV protection, high-contrast settings on devices, large-print materials, and good task lighting make daily life smoother, while orientation and mobility training can build confidence outdoors. Work, school, and driving may require adjustments or alternative plans, but assistive technology and disability accommodations help keep goals on track. For family and friends, patience, clear verbal cues, and small environmental tweaks—like decluttering pathways and consistent object placement—can make a big difference and reduce frustration for everyone.
Treatment and drugs
Treatment for cone-rod dystrophy 11 focuses on protecting remaining vision, easing day-to-day challenges, and supporting eye health, since there’s currently no cure to reverse vision loss. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as high-dose antioxidant vitamins only when indicated, careful sun and glare protection with tinted lenses, and management of related issues like dry eye to improve comfort. Low-vision rehabilitation is central: specialized glasses or electronic magnifiers, contrast-enhancing filters, large-print or audio tools, and mobility training can help many people stay independent at work, school, and outdoors. Genetic counseling can explain inheritance and discuss whether genetic testing may guide care or eligibility for clinical trials; some centers may also discuss emerging options like gene-based therapies being studied, though these are not yet standard. Keep track of how you feel, and share this with your care team so they can adjust supports, check for treatable complications, and connect you with vision services and community resources.
Non-drug treatment
Living with Cone-rod dystrophy 11 affects reading, recognizing faces, and getting around, especially in bright light or at dusk. Non-drug treatments often lay the foundation for day-to-day independence. Getting support soon after early symptoms of Cone-rod dystrophy 11 appear can help you keep routines and confidence. Care plans are tailored, and they usually blend vision rehab, tools, and safety strategies.
A low-vision specialist teaches practical ways to use remaining sight. You’ll learn strategies for reading, navigation, and daily tasks at home and work.
Training builds safe travel skills indoors and outdoors. You practice cane techniques, route planning, and using landmarks or apps for wayfinding.
Screen readers, magnifier apps, and smart speakers can make reading and navigation easier. Some devices describe scenes or read text aloud in real time.
Adjusting brightness, using task lamps, and adding high-contrast labels can reduce eyestrain. Simple changes at home often make tasks faster and safer.
Your genes may have an impact on how drugs work for you
Some medicines for people with cone-rod dystrophy 11 can work differently depending on inherited gene changes that affect how cells process or respond to treatment. Genetic testing may guide dosing, flag side‑effect risks, and identify who could benefit from gene‑targeted therapies.
Pharmacological treatments
There’s no medicine that can cure or stop cone-rod dystrophy 11, but a few drugs may help treat complications like swelling in the center of the retina and improve day‑to‑day vision. Not everyone responds to the same medication in the same way. Medicines can’t reverse vision that’s already lost, even when early symptoms of cone-rod dystrophy 11 first show up, but they may sharpen remaining sight in select situations. Your eye specialist will tailor choices to whether there is swelling, inflammation, or other features on exam.
Acetazolamide or methazolamide by mouth, or dorzolamide or brinzolamide as eye drops, can reduce fluid buildup in the macula and sometimes improve clarity. These are used when cone-rod dystrophy 11 causes cystoid macular edema seen on exam. Dosing may be increased or lowered gradually to balance benefits and side effects like tingling or fatigue.
Nonsteroidal drops such as ketorolac or bromfenac, or short courses of steroid drops like prednisolone acetate, may calm inflammation around the macula. This can ease swelling and light sensitivity, though steroids can raise eye pressure and require monitoring. They are often tried if carbonic anhydrase inhibitors aren’t enough.
Injections into the eye (intravitreal) with triamcinolone or a dexamethasone implant may be considered for stubborn macular swelling. These are off-label in cone-rod dystrophy 11 and used selectively due to risks like increased eye pressure or cataract. Close follow-up is essential to watch for side effects.
High‑dose vitamin A is not recommended for cone-rod dystrophy 11, as it has not shown clear benefit and may pose risks in inherited retinal disease. Only take vitamin supplements your clinician specifically advises, since interactions and overdosing can occur. Ask your doctor why a specific drug was recommended for you.
Genetic influences
In cone-rod dystrophy 11, changes in a single gene are the main driver, altering how the eye’s light-sensing cells develop and work over time. These gene changes can be inherited, and the pattern varies by family—some children are affected when they inherit a faulty copy from both parents (who may have no symptoms), while others inherit a single changed copy from an affected parent. Family history is one of the strongest clues to a genetic influence. If you’re wondering “is cone-rod dystrophy 11 hereditary?”, the short answer is that it often is, though a new, first-in-the-family gene change can also occur. Genetic testing for cone-rod dystrophy 11 can confirm the gene involved, identify carriers in the family, and help estimate the chance of the condition in future pregnancies. A genetics professional can also explain why the same gene change may affect relatives differently, including age of onset and the degree of vision change.
Is Cone-rod dystrophy 11 genetic?
Genetics are central in Cone-rod dystrophy 11; it’s caused by inherited gene changes, most often affecting photoreceptor function. Variants can run in families with autosomal dominant or recessive patterns. Different mutations influence age at onset, severity, and progression.
Pharmacogenetics—how genetics influence drug effects
The specific gene change behind Cone-rod dystrophy 11 can shape care now and in the future. Alongside medical history and detailed eye exams, genetic testing can guide prognosis and trial options, and in a few situations inform medicine choices. Right now there’s no approved drug that reverses Cone-rod dystrophy 11, so treatment focuses on low-vision support and managing complications like retinal swelling with drops or tablets. If such medicines are used, common drug–gene differences that affect how quickly the liver processes a drug can influence side effects or dosing, but routine pharmacogenetic testing for Cone-rod dystrophy 11 isn’t standard. The bigger genetic impact is matching people to research, which can broaden treatment options for Cone-rod dystrophy 11, including gene-directed or gene-agnostic approaches, with eligibility tied to the exact variant. Genes aren’t the whole story, though—age, stage of retinal damage, other health conditions, and your goals all help determine the best plan.
Interactions with other conditions
Other eye conditions can occur alongside Cone-rod dystrophy 11 and make day-to-day vision tougher to manage. Doctors call it a “comorbidity” when two conditions occur together. Cataracts, glaucoma, or high levels of nearsightedness can add to glare, blur, and difficulty with contrast, so tasks like reading a menu under bright lights or noticing curbs at dusk may feel even harder. Health issues that also affect the retina—such as diabetes or high blood pressure—can further strain the back of the eye and may complicate how quickly early symptoms of Cone-rod dystrophy 11 are noticed. Certain medicines known to stress the retina, including some antimalarial drugs or high-dose vitamin A, may pose added risk and usually warrant a careful review with your eye specialist. Interactions can look very different from person to person, so coordinated care between your eye doctor and your primary care team helps tailor monitoring and treatment when Cone-rod dystrophy 11 occurs with other health problems.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of fading daylight vision and trouble with fine detail that seemed to pass from one generation to the next. A teenager might squint in bright sun and miss a ball coming straight at them, while an older relative recalls similar struggles since youth. These lived stories came long before modern names like cone-rod dystrophy 11 were used.
First described in the medical literature as inherited problems affecting the eye’s light-sensing cells, these conditions were initially grouped broadly. Doctors relied on what people reported—glare sensitivity, color changes, and central blur—along with drawings of visual fields and simple night-vision tests. Over time, descriptions became more precise as eye doctors learned to record electrical signals from the retina. Those tests showed that cone cells, which handle color and sharp central vision, were affected earlier than rod cells, which support night and side vision. This pattern helped set cone-rod dystrophies apart from other retinal disorders.
As medical science evolved, families with similar vision changes were followed across decades. Careful family trees hinted at different inheritance patterns. Some clusters suggested a single-gene cause, but the exact genes were unknown. With each decade, better imaging allowed clinicians to see subtle thinning in the macula—the area responsible for detailed sight—while peripheral rod function often declined later. These clinical features helped define what we now call cone-rod dystrophy 11.
Advances in genetics then connected the dots. DNA research now explains why some families share the same course of vision change: a change in a specific gene tied to photoreceptor function. Once considered rare, now recognized as part of a diverse spectrum, cone-rod dystrophy 11 became one of several numbered forms linked to different genes but overlapping symptoms. Naming it this way—by its genetic cause—helped doctors counsel families about chances of passing it on and the likely pace of changes over time.
In recent decades, awareness has grown thanks to wider genetic testing and patient registries. People with cone-rod dystrophy 11 are now more likely to receive a precise diagnosis rather than a broad label. This clarity matters. It supports tailored low-vision resources, connects families to research, and steadily improves estimates of onset age and early symptoms of cone-rod dystrophy 11. Not every early description was complete, yet together they built the foundation of today’s knowledge.